Under the deal, which follows on a previous collaboration between the companies entered in 2008, Kinaxo will apply its quantitative phosphoproteomics platform PhosphoScout to assist in drug development.
As part of the deal, Kinaxo will use its PhosphoScout phosphoproteomics technology to assess drugs under development at Takeda.
The acquisition of the chemical proteomics firm allows Evotec it "to take earlier educated decisions on drug efficacy, safety, and response in patients."
Kinaxo will use it mass spectrometry-based technologies to quantitatively analyze post-translational modifications in proteins on a proteome-wide scale.
Kinaxo will apply its technologies to deconvolute molecular targets of compounds on which the drug company is currently performing drug discovery work.
The Japanese drug firm will use Kinaxo's Cellular Target Profiling, KinAffinity, and PhosphoScout products.
Kinaxo’s phosphoproteomic tools will support targeted treatment development at Roche.
The German biotech plans to invest €3 million to €4 million in biomarker development over the next two years.
Christian Jurinke, Jeff Protentis, Jürgen Schumacher
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.